Member Info for ahha

We know from the partnered pipeline of BTG that Onyx is also developing ONX0801, which is the new code for former BGC 945, and which was licensed by ONYX from BTG several years ago. With Onyx being absorbed by a stronger pharma major as Bayer, the development of BGC 945, and royalties for BTG, just could come sooner than expected. I think the long awaited SUPERGROWTH of BTG is almost upon us! BUY, BUY, BUY!

What a joke!!! Come on..........who are you trying to kid? I stongly disagree..........BUY! BUY! BUY! And should a large number decide to take Finncap's advice and the price falls, I personally will buy even more. I consider this share to be one of those rock solid Warren Buffett shares....don't sell a single share!

At Last some comment from someone else!! It's good to know that I am not the only person in the world that owns BTG shares. I've felt like one crying in the wilderness..." make straight the way of BTG!" This is EXCELLENT NEWS!!! And amazingly the shares have gone down in value as a result. For many years it was always expected that Varisolve.......or VANISH as it it is cleverly renamed for marketing purposes, would add very considerable value to the company. I have waited patiently for this news for many years......after many draw backs and disappointments. MY ADVICE IS BUY AS MANY OF THESE SHARES AS U CAN AFFORD and wait patiently for the true value of these shares to be realised. Because, when the sums are done......taking also into account the revenue of BTG's other successful products, the future looks very rosy!!! There is only one thing that puzzles me. Why haven't the Director's shown more faith in the company and bought more shares?

VARISOLVE will be a major money spinner when it comes to market - we have waited 10 years or more for this to come to the market in the US........so why is the company being so low key about it? Together with othewr fine drugs producing vastly increased revenues 2012/13 looks to deliver BUMBER PROFITS and at long last, a dividend! Louise Makin, BTG's CEO, commented: "We have delivered a strong financial and operating performance across the business. Our development programmes are on track and we have made good progress in our Interventional Medicine business. We anticipate another busy year ahead including the US launch of Voraxaze®, our planned New Drug Application for our varicose veins programme Varisolve® and data from AstraZeneca's Phase IIb study of AZD9773."

Louise Makin, BTG's CEO, commented: "We have delivered a strong financial and operating performance across the business. Our development programmes are on track and we have made good progress in our Interventional Medicine business. We anticipate another busy year ahead including the US launch of Voraxaze®, our planned New Drug Application for our varicose veins programme Varisolve® and data from AstraZeneca's Phase IIb study of AZD9773."

"But over the next two to three years, Peel Hunt thought FTSE 250-listed BTG, down 4.4 to 355½p, could be a viable takeover target" Maybe some bird of prey has spotted that it has 50million in cash.......and some block busters in the pipeline? hmmmmmmmmmmmm

she is breaking new ground.......am I the ONLY investor on this sight to notice?

Tom Winnifrith Share guru extrordinare sai so on chanel 4 TV over 10 years ago and i have held BTG ever since. Good old Tom!

I remember Tom Winnifrith saying so on a share programe on chanel 4 over 10 years ago ! I,ve held them ever since. Good old Tom!

This little beauty is creeping up slowly........not attracting any attention to itself......"but she just keep rolling along" I would not be at all surprised if there was not some really fabulous news in the pipeline.........and no doubt the institutions are stocking up. I've noticed that this share has incredible resiliance in bed times, despite it's very high P/E . I THINK IT'S TIME FOR SOME FIREWORKS ON THIS SHARE.....do you agree Mulled Wine? I think £4.50 short term is not unrealistic!!!

Fear not! Lord Chadlington will not cease from mental fight, nor will his sword sleep in his hand, till he has built Jerusalem in England's green and pleasant land! In short, the company is in highly capable hands and only a little unexpected good news will restore the fortunes of this share....AND you will get 7% yeild and a juicy dividend while you wait.

I note that 1.6 million shares were sold today on the latest NHT results.........in the recent past, this has been a sign of future share price increase. The results were not brilliant, but neither were they devastating and they provide a good basis, at the very least, for share price stability. I suspect that as the market moves higher on the back of USA election euphoria and market manipulation of positive news regarding the world economy NHT will build upon it's present price. It must not be overlooked that it has a current yeild of 7% and as long as market expectaations are maintained the share price and the dividend look secure. My target price up to the end of October is around 75p

In my opinion these shares are still half the price they should be! And just look at the juicy dividend!!

I have waited what seems like an eternity for Varasolve to come to the market.........there have been so many trails and retrails on the way..........but 10 years ago or more the shares were £4.00.....and they have never got to that level since. I am sure there is enormous potential for this share to go to £6.00 and we cannot be far now for Varisolve to come to the market. Also the share has huge amounts of cash and many other block busting drugs. Yet in all these years, still no dividend! Patience will bring rewards I am sure.

Despite the challenging macro-economic backdrop, the Group's new business pipeline is strong and the Board is confident of improved trading in 2012 compared to 2011. The benefits of the brand re-organisation continue to be felt and the Group is well positioned to service larger international clients on longer contract terms. Work has now started on a number of the new mandates announced in the second half of 2011. Group budgets for 2012 are underpinned by a number of such clients, reducing dependence on one-off project revenues. Balance Sheet, Earnouts and Dividends Huntsworth's Balance Sheet remains robust and the Group continues to trade comfortably within its banking covenants. Net debt for year end 2011 is expected to be circa £71m. Earn outs peaked in 2011 with total payments of £18m of which over £17m was settled in cash. Earn out liabilities through until 2016 are approximately £16m of which £9m can be settled in cash or shares at the Group's option. The highest earn out liability in any one year is expected to be no more than £5.5m, half of which can be settled in shares. In light of current trading, the outlook for the remainder of 2012 and the cash generation profile of the Group, the Board expects that total dividends paid in respect of 2011 will not be less than those paid in 2010.

Britain's BTG Plc will also benefit from expanded use of Zytiga as it is entitled to royalty payments on sales of the drug. BTG, originally licensed the drug to Cougar Biotechnology, which was acquired by J&J. Zytiga, a pill given once daily, works by inhibiting production of hormones called androgens that can fuel tumor growth in prostate cancer patients.

I have been very patient with these rock solid shares. I have followed them for over 10 years now. They have plenty of cash and a number of block busting drugs in the pipeline. I would not be surprised to see them at £4.50 to £6.00 in the next 12 months. Does anyone agree? I am very interested to see the effect of the much awaited VARASOLVE on the future of the company!!

Why do the shares move from 43.35p to 44.50p after a sell of over 2 million shares today? I do not understand the logic.......can anyone explain?

Sorry Mulledwine 84p NAV and 26% debt, not 23% as stated in previous message...... and intangible assets worth £1.19p a share. Has all this changed now.........like the share price? Have all these facts reduced by half like the share price? What is your opinion? Is Huntsworth about to go bust? I should be gratified to benefit from your wisdom.

Investor's Chronical article 2010: HUNTSWORTH NET ASSETT VALUE 84p A SHARE with 23% debt and intangible assets worth £1.19p Have these fundamentals changed now? Or is HUNTSWORTH the most unbelievably underpriced asset? Maybe Mulledwine has an answer for us? I would appreciate your opinion.